You just read:

Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for the Treatment of Neuronal Ceroid Lipofuscinoses With PLX-100

News provided by

Polaryx Therapeutics, Inc.

Dec 11, 2017, 09:00 ET